Member Info for beinthelead

Bella - the safety data sheet research was not the vehicle to inform us that the test relied on an antibody. After all, the data sheet didn’t explain its purpose. It could have been ‘cosmetic’ for all we knew.

Nevertheless, Timster is correct. AS explicitly stated that adaptation was a few weeks in the face of effective mutations. We now know this was a lie. And we know this because he doesn’t know what regulatory impact the change will have.

Let’s see what happens.

Absolutely Timster. He’s misled the market. Something I mentioned the other day that I struggle to accept.

Mologic we’re the test designer. How/what led to this is anyones guess. I suggest it was a time to market decision. Good call, but with risk. Risk now realised. I’d have done the same.

They need to bin that AB. Coming back with an all Affimer LFT (most thought it was anyway), and why, will give the Dx biz a boost. I’m sure this will be the angle.

Zoom - exactly that. It’s about credibility.

Ah, sorry.

Nothing to worry about. It’s AIM.

Wac - hardly. Are you new to investing??

Was it not Elrico? This information should be delivered first hand via RNS. My only gripe with the CEO.

Good honest TU. Why I really like the CEO - no fluff.

Underpinned analysts forecasts. Influencer targeting. Lovely stuff.

Croda will drag on, as normal.

This was not issued in response to TW’s podcast.

And don’t mention POINT. Avacta sub-licence.

Truant is a troll - ignore and beware.

You seem well acquainted. Can you point us to this contract and clause.

I’m sure that if he was out ramping the cancer stuff as he was the LFT you could insert your same ‘cause for concern line’. What a waste of time. Why bother? Honestly.

Do you guys see yourselves as Robin Hood or Batman? Nobody needs saving.

Thanks.

Albeit Phase 3 trial results. But £9bn for a fraction of the impact PreCision could have.

Where are the new users that landed just after TW’s *free to air* podcast? Answers on the back of an LFT.

I’m with you Zoom. With have another beetlejuice investor.

So from a technical chart perspective, you’re not sure. Cheers.

What if news lands before 20-23p. What happened then? You’ve got experience of this, having held for 10 years.

We’d all like to be knocked for six. The product should be front and centre.

Nobody knows what going on. Speculating either way is confirmation bias. In the absence of any update via RNS, we can only hope.

It’s disgraceful that he’s having lengthy chats with a CEO then pumping a stock. The guy is not very credible.

Stuart Ashman appears to be a credible guy. If it happened, it’s another reason for concern.

Drip feeding is the correct strategy.

Or be like these guys - 1 hour charts are where it’s at

https://twitter.com/Stocksniper28/status/1493544920489115651?s=20&t=eGUZgNBiV3MuUxu027hO7A

Got to be parody accounts. Busy fools.